demonstrated no overall survival (OS) benefit of margetuximab plus chemotherapy over trastuzumab plus chemotherapy in patients with pretreated human epidermal growth factor receptor 2 (HER2)‐positive advanced breast cancer (ABC),1 despite the statistically significant improvement in progression‐free survival (PFS) previously reported in JAMA Oncology.2 Here, ERBB2 is linked to breast carcinoma.